Critics Warn Biden Drug Pricing Rule Could Stifle Future Medical Breakthroughs

According to the commentary, the Inflation Reduction Act allowed CMS to negotiate Medicare drug prices, a practice the author likens to outright price-setting. A forthcoming CMS rule aims to broaden the criteria for linking newly approved drugs to existing price caps, potentially covering follow-on treatments with distinct formulations. Citing a study that shows a 70% decline in small-molecule drug investment, the author contends that this could deter companies from pursuing costly Phase 3 trials and manufacturing changes needed for better delivery methods.

The piece highlights how such constraints might prevent advances like shorter infusion times for cancer drugs, which would improve patient access and free up clinical resources. It also questions whether CMS is exceeding the authority granted by Congress, suggesting the FDA should remain the sole arbiter of drug distinctiveness. The author calls for alternative strategies, such as increasing competition and curbing insurer opacity, to lower drug costs without discouraging innovation.